Q32 Bio Inc. (QTTB): Nasdaq/NYSE listing notice — Homology Medicines receives Nasdaq bid price deficiency notice; compliance deadline June 26, 2024

Q32 Bio Inc.

Received Nasdaq deficiency notice on Dec 29, 2023 for bid price below $1.00 for 30 consecutive business days.
Has 180 calendar days, until June 26, 2024, to regain compliance by closing at $1.00+ for 10 consecutive business days.
Plans to seek stockholder approval for reverse stock split in connection with proposed merger with Q32 Bio.
If not compliant by June 26, may qualify for second 180-day period by transferring to Nasdaq Capital Market.
Failure could lead to delisting, subject to appeal; no assurance of success.

item 3.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Q32 Bio Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

December 29, 2023, Homology Medicines, Inc. (the “ Company ” or “ Homology ”) received a letter (the “ Nasdaq Notification ”) from The Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that, for the last thirty (30) consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1) (the “ Minimum Bid Price Requirement ”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided 180 calendar days, or until June 26, 2

View on SEC.gov

Browse all listing & compliance notices →

Q32 Bio Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-001519

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.